Regencell Bioscience logo

Regencell Bioscience(NASDAQ) RGC

Market Cap$3.64BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)+2,560%
5 Year+1,362%
1 Year-60%
1 Month+26%
Premium Feature
Moneyball Superscore
22/100
$7.34
-3.80%
-0.29Today
After hours$7.36+$0.02 (+0.27%)
Regencell Bioscience last closing stock price
MetricPriceDate
Last closeUSD 7.352026-10-09
Regencell Bioscience stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+7.77%USD 6.822026-10-02
1 month+25.64%USD 5.852026-09-09
3 month+25%USD 5.882026-07-10
Year to date-65%USD 21.002025-12-31
1 year-60.14%USD 18.442025-10-09
3 year+1,544.88%USD 0.452023-10-10
5 year+1,361.54%USD 0.502021-10-08
Since inception+2,560.01%USD 0.282021-07-16

Regencell Bioscience Financials at a Glance

Market Cap

$3.64BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$15.29M

EPS (TTM)

-$0.02

P/E Ratio

-311.44

Dividend

$0.00

Beta (Volatility)

0.29 (Low)

Price

$7.34

Volume

118,724.666

Open

$7.73

Previous Close

$7.35

Daily Range

$7.28 - $7.75

52-Week Range

$4.51 - $69.00

Estimated Earnings Date

Oct 28, 2026

RGC News

23_07_04 A scale showing risk from low to high with the pointer on the dial on high _MF Dload

Here's Why I Wouldn't Touch Regencell Bioscience With a 10‑Foot Pole Right Now

Reuben Gregg BrewerMar 6, 2026
22_01_26 A person looking at a computer screen with a look of unpleasant surprise _GettyImages-1216968860

Don't Even Think About Buying Regencell Bioscience Stock Until You See This 1 Red Flag

Reuben Gregg BrewerMar 5, 2026
Getty - surprised amazed wow

This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock)

Selena MaranjianNov 24, 2025
Paper Certificate Shares Invest Stock Split Market Reverse Getty

Prediction: Wall Street's Latest Stock-Split Stock -- Up 60,120% Year-to-Date -- Is Going to Implode... It's Just a Matter of Time

Sean WilliamsJun 20, 2025

RGC: Motley Fool Moneyball Superscore

22

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Regencell Bioscience

Regencell Bioscience Holdings Limited specializes in integrating Traditional Chinese Medicine (TCM) with modern scientific approaches to develop treatments for neurocognitive disorders and infectious diseases. The company focuses on addressing unmet medical needs through innovative therapies, supported by an extensive intellectual property portfolio that underscores its research and development commitments.

Products and Services

Therapies for neurocognitive disorders utilizing TCM and scientific methodologies

Treatments for infectious diseases

What Makes Regencell Bioscience Holdings Limited Special

Regencell stands out by merging ancient TCM practices with modern science to create unique therapies. Its robust pipeline is backed by a strong intellectual property strategy. The company's visionary leadership combines expertise in biosciences and TCM, aiding in navigating regulatory challenges and capitalizing on market opportunities.

Five Things You Need to Know

Focuses on neurocognitive disorders and infectious diseases using TCM-based treatments.

Significant intellectual property portfolio supports its research and development.

Driven by a management team with expertise in biosciences and TCM.

Engages in strategic partnerships with academic institutions and healthcare providers.

Aims to expand its geographic footprint and emphasize personalized medicine for growth.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10

CEO

Yat-Gai Au

Website

www.regencellbioscience.com

Headquarters

Hong Kong, KY1-1107, HK

RGC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-160.64%

Return on Capital

-85.92%

Return on Assets

-79.45%

Earnings Yield

-0.32%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.64BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

495.88M

Volume

118.72K

Avg. Volume

198.40K

Financials (TTM)

Gross Profit

-$404.54K

Operating Income

-$15.49M

EBITDA

-$14.85M

Operating Cash Flow

-$7.70M

Capital Expenditure

-$2.00

Free Cash Flow

-$7.70M

Cash & ST Invst.

$14.19M

Total Debt

$295.81K

Regencell Bioscience Performance Analysis

Regencell Bioscience annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 0N/A
20242024-06-30USD 0N/A
20252025-06-30USD 0N/A
20262026-06-30USD 0N/A
Regencell Bioscience sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-29N/A
Q42025-06-30N/A
Q22025-12-31N/A
Q42026-06-30N/A
Regencell Bioscience annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD -0.01-22.7%
20242024-06-30USD -0.01-26.9%
20252025-06-30USD -0.01-17.2%
20262026-06-30USD -0.02229.2%
Regencell Bioscience sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-2917.8%
Q42025-06-305.4%
Q22025-12-31-205.7%
Q42026-06-30-20.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$363.70K

N/A

Gross Margin

0.00%

N/A

Market Cap

$3.64BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$364.47M

N/A

Employees

10

N/A

Net Income

-$6.38M

-571426.8%

EBITDA

-$6.02M

-3910.3%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$14.19M

+78.3%

Total Debt

$295.81K

+245.0%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$59.50K

+129.4%

Short Term Debt

$236.31K

+295.1%

Return on Assets

-79.45%

N/A

Return on Invested Capital

-87.44%

N/A

Free Cash Flow

-$5.10M

-154.7%

Operating Cash Flow

-$5.10M

-155.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AMLXAmylyx Pharmaceuticals, Inc.
$28.14+3.46%
HRMYHarmony Biosciences Holdings, Inc.
$40.28+1.72%
LBRXLB Pharmaceuticals Inc Common Stock
$37.22+7.54%
PRAXPraxis Precision Medicines, Inc.
$259.86-1.40%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About RGC

What is the current price of Regencell Bioscience?

Regencell Bioscience is trading at $7.35 per share.

What is the 52-week range for Regencell Bioscience?

Over the past 52 weeks, Regencell Bioscience has traded between $4.51 and $69.00.

How much debt does Regencell Bioscience have?

As of the most recent reporting period, Regencell Bioscience reported total debt of $295.81K.

How much cash does Regencell Bioscience have on hand?

Regencell Bioscience reported $14.19M in cash and cash equivalents in its most recent financial results.

What is Regencell Bioscience’s dividend yield?

Regencell Bioscience does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services